Form 8-K - Current report:
SEC Accession No. 0001558370-25-000150
Filing Date
2025-01-13
Accepted
2025-01-13 07:30:13
Documents
17
Period of Report
2025-01-13
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crvs-20250113x8k.htm   iXBRL 8-K 48728
2 EX-99.1 crvs-20250113xex99d1.htm EX-99.1 27061
3 GRAPHIC crvs-20250113x8k006.jpg GRAPHIC 42082
4 GRAPHIC crvs-20250113xex99d1001.jpg GRAPHIC 5572
5 GRAPHIC crvs-20250113xex99d1002.jpg GRAPHIC 42130
  Complete submission text file 0001558370-25-000150.txt   369908

Data Files

Seq Description Document Type Size
6 EX-101.SCH crvs-20250113.xsd EX-101.SCH 3279
7 EX-101.LAB crvs-20250113_lab.xml EX-101.LAB 15265
8 EX-101.PRE crvs-20250113_pre.xml EX-101.PRE 9934
19 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20250113x8k_htm.xml XML 4692
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 25524804
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)